Unknown

Dataset Information

0

Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer.


ABSTRACT: BACKGROUND:National Cancer Institute phase I #7336 and phase II #8327 clinical trials explored the safety and efficacy of triapine (NSC #663249) added to cisplatin radiochemotherapy in untreated patients with advanced-stage cervical cancer. Triapine inhibits ribonucleotide reductase, the rate-limiting enzyme responsible for DNA-building deoxyribonucleotides, and thereby, enhances radiochemosensitivity by prolonging DNA repair time. Here, we report 3-year efficacy endpoints of pelvic locoregional relapse rate, disease-free, and overall survivals. METHODS:Eligible patients with bulky IB-IIIB cervical cancer underwent three-times weekly triapine (25 or 50?mg/m(2)), once-weekly cisplatin (40?mg/m(2)), and conventional daily pelvic radiation followed by brachytherapy. A cumulative incidence method estimated pelvic locoregional relapse rates. Disease-free survival was measured from radiochemotherapy start date to the date of first relapse or cancer-related death. Overall survival was measured from radiochemotherapy start date to the date of any-cause death. The Kaplan-Meier method estimated survivals. FINDINGS:Between 2006 and 2011, 24 untreated patients with cervical cancer met criteria for reporting in this study. A median 3.4?years of follow-up time (range, 0.3-7.6?years) has been observed. All had squamous cancers and the majority had either node-positive stage IB-IIA (33%) or stage IIIB (42%) disease. The 3-year pelvic locoregional relapse rate, disease-free survival, and overall survival were 4% [95% confidence interval (CI), 0-20%], 80% (95% CI: 71-89%), and 82% (95% CI: 74-90%), respectively. INTERPRETATION:Triapine radiochemotherapy was safe, active, and effective in patients with untreated advanced-stage cervical cancer, worthy of randomized clinical trial study.

SUBMITTER: Kunos CA 

PROVIDER: S-EPMC4109518 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer.

Kunos Charles A CA   Sherertz Tracy M TM  

Frontiers in oncology 20140724


<h4>Background</h4>National Cancer Institute phase I #7336 and phase II #8327 clinical trials explored the safety and efficacy of triapine (NSC #663249) added to cisplatin radiochemotherapy in untreated patients with advanced-stage cervical cancer. Triapine inhibits ribonucleotide reductase, the rate-limiting enzyme responsible for DNA-building deoxyribonucleotides, and thereby, enhances radiochemosensitivity by prolonging DNA repair time. Here, we report 3-year efficacy endpoints of pelvic loco  ...[more]

Similar Datasets

| S-EPMC5949312 | biostudies-literature
| S-EPMC6433810 | biostudies-literature
| S-EPMC5796580 | biostudies-literature
| S-EPMC4915007 | biostudies-literature
| S-EPMC4150919 | biostudies-literature
| S-EPMC3917787 | biostudies-literature
| S-EPMC8493709 | biostudies-literature
| S-EPMC6516889 | biostudies-literature
| S-EPMC6855659 | biostudies-literature
| S-EPMC5177708 | biostudies-literature